Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Maio

Showing results (21-30 of 250) with videos related to

Pageof 25
Sort By:
Oncogene|October 7, 2003
Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?Maresa Altomonte, Ester Fonsatti, Alberto Visintin, et al.
Seminars in Oncology|November 16, 2010
Biology and clinical applications of CD40 in cancer treatmentEster Fonsatti, Michele Maio, Maresa Altomonte, et al.
Seminars in Oncology|November 16, 2010
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapyKim A Margolin, Anna Maria Di Giacomo, Michele Maio
Seminars in Oncology|November 16, 2010
Anti-CTLA-4 antibody adjuvant therapy in melanomaAlexander M M Eggermont, Alessandro Testori, Michele Maio, et al.
Oncogene|October 7, 2003
Epigenetic targets for immune intervention in human malignanciesMichele Maio, Sandra Coral, Elisabetta Fratta, et al.
Current Oncology Reports|October 22, 2021
COVID and Lung CancerLuana Calabrò, Giulia Rossi, Alessia Covre, et al.
Cancer Immunology, Immunotherapy : CII|June 27, 2018
Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challengeLuana Calabrò, Aldo Morra, Robin Cornelissen, et al.
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Epigenetic markers of prognosis in melanomaLuca Sigalotti, Elisabetta Fratta, Giulia Parisi, et al.
International Journal of Cancer|April 22, 2003
Methylation-regulated expression of HLA class I antigens in melanomaEster Fonsatti, Luca Sigalotti, Sandra Coral, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2020
SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcomeAnna M Di Giacomo, Elisabetta Gambale, Santa Monterisi, et al.
Pageof 25

Showing results (21-30 of 250) with videos related to

Sort By:
Pageof 25
Oncogene|October 7, 2003
Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?Maresa Altomonte, Ester Fonsatti, Alberto Visintin, et al.
Seminars in Oncology|November 16, 2010
Biology and clinical applications of CD40 in cancer treatmentEster Fonsatti, Michele Maio, Maresa Altomonte, et al.
Seminars in Oncology|November 16, 2010
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapyKim A Margolin, Anna Maria Di Giacomo, Michele Maio
Seminars in Oncology|November 16, 2010
Anti-CTLA-4 antibody adjuvant therapy in melanomaAlexander M M Eggermont, Alessandro Testori, Michele Maio, et al.
Oncogene|October 7, 2003
Epigenetic targets for immune intervention in human malignanciesMichele Maio, Sandra Coral, Elisabetta Fratta, et al.
Current Oncology Reports|October 22, 2021
COVID and Lung CancerLuana Calabrò, Giulia Rossi, Alessia Covre, et al.
Cancer Immunology, Immunotherapy : CII|June 27, 2018
Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challengeLuana Calabrò, Aldo Morra, Robin Cornelissen, et al.
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Epigenetic markers of prognosis in melanomaLuca Sigalotti, Elisabetta Fratta, Giulia Parisi, et al.
International Journal of Cancer|April 22, 2003
Methylation-regulated expression of HLA class I antigens in melanomaEster Fonsatti, Luca Sigalotti, Sandra Coral, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2020
SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcomeAnna M Di Giacomo, Elisabetta Gambale, Santa Monterisi, et al.
Pageof 25